Omeros (OMER) Receivables - Net (2010 - 2026)
Omeros (OMER) posted Receivables - Net of $12.0 million for Q1 2026, up 10.21% sequentially from $10.9 million in Q4 2025, and up 70.04% YoY from $7.1 million in Q1 2025.
Analysis
Omeros (OMER) Receivables - Net (2010 - 2026) Analysis & Trends
Omeros has reported Receivables - Net for 17 years, with the latest figure at $12.0 million in Q1 2026.
- Quarterly Receivables - Net rose 70.04% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 70.04% YoY) and the FY2025 annual result came in at $10.9 million, up 41.06% from the prior year.
- Receivables - Net improved to $12.0 million in Q1 2026 per OMER's latest filing, from $10.9 million in the prior quarter.
- Over five years, Receivables - Net peaked at $213.2 million in Q4 2022 and troughed at $6.3 million in Q2 2025.
- A 5-year average of $21.6 million and a median of $8.1 million in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 458.83% in 2022, then plunged 96.2% in 2023.
- Over 5 years, Receivables - Net stood at $213.2 million in 2022, then slumped by 96.2% to $8.1 million in 2023, then declined by 4.41% to $7.7 million in 2024, then soared by 41.06% to $10.9 million in 2025, then climbed by 10.21% to $12.0 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $12.0 million, $10.9 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.30 Mn |
| Mar 31, 2026 | 12.03 Mn |
| Dec 31, 2025 | 10.92 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | 6.28 Mn |
| Mar 31, 2025 | 7.08 Mn |
| Dec 31, 2024 | 7.74 Mn |
| Sep 30, 2024 | 6.39 Mn |
| Jun 30, 2024 | 8.08 Mn |
| Mar 31, 2024 | 7.64 Mn |
| Dec 31, 2023 | 8.10 Mn |
| Sep 30, 2023 | 6.88 Mn |
| Jun 30, 2023 | 11.20 Mn |
| Mar 31, 2023 | 10.03 Mn |
| Dec 31, 2022 | 213.22 Mn |
| Sep 30, 2022 | 13.90 Mn |
| Jun 30, 2022 | 14.50 Mn |
| Mar 31, 2022 | 16.30 Mn |
| Dec 31, 2021 | 38.16 Mn |
| Sep 30, 2021 | 33.90 Mn |